Slow-cycling cancer cells may explain why breast cancer returns decades later Written byBree Foster, PhD

Slow-cycling cancer cells may explain why breast cancer returns decades later Researchers identify a slow-cycling, therapy-tolerant state in breast cancer cells linked to Rac1 signaling and late metastatic relapse. Written byBree Foster, PhD https://www.drugdiscoverynews.com/slow-cycling-cancer-cells-may-explain-why-breast-cancer-returns-decades-later-17171 A new study has uncovered a previously underappreciated mechanism that may help explain why estrogen receptor-positive (ER+) breast cancer can return years — or even decades — after patients are declared cancer-free.

Women, power and cancer: from Commission to collective action Weds, May 20, 2026 16:00 - 17:30 CEST

https://iarc2026conf.iarc.who.int/en/programme/partners-sessions/28?utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-93Jtrb3X1iC0oBEFxHgT4JGvDc1VZ6ghJPGToVE4cXOM9r-2YsKHtFrUKJ-lg4jujAaZ34tZyrpUsUIK5iTNDVT7VPIg&_hsmi=416559897&utm_content=416559897&utm_source=hs_email Executive summary Women interact with cancer in complex ways, as healthy individuals participating in cancer prevention, as patients, as health professionals, researchers, policymakers, and as unpaid caregivers. In all these domains, women often are subject to overlapping forms of discrimination, such as due to age, race, ethnicity and socio-economic status, that render them structurally marginalized. These myriad factors can restrict a woman’s rights and opportunities to avoid cancer risks, are a barrier to diagnosis and quality cancer care, maintain an unpaid caregiver workforce that is predominantly female, and hinder women’s professional advancement. The Lancet Commission on women, power and cancer was created to address urgent questions at the intersection of social inequality, cancer risk, and outcomes, and the status of women in society. https://www.thelancet.com/do-content/women-power-and-cancer-lancet-commission?dgcid=hubspot_email_conferencealerts_iarc26_lancetwomenpowercancer23&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_J48TcsLLek7UXqvUMllEXgWEWSSDXtwJu456UuZimJ9j0pbJaLaQXnRtrH0Z_RC8yfJt41RDUqxvm4kNCc7v0XOe9SA&_hsmi=416559897&utm_content=416559897&utm_source=hs_email

Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer Authors: Peter Schmid, MD, PhD, FRCP; Kevin Kalinsky, MD, MS, FASCO; Frédérique Penault-Llorca, MD, PhD

https://www.medscape.org/viewarticle/clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h?page=1&src=mkmcmr_driv_stan_mscpedu_260512-OUS-HONC-clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h-cta&uac=148436CN

Early-Onset Colorectal Cancer Risk Factors Identified in Two Studies Damian McNamara, MA May 13, 2026 ++ ++ + + +

Early-Onset Colorectal Cancer Risk Factors Identified in Two Studies Damian McNamara, MA https://www.medscape.com/viewarticle/early-onset-colorectal-cancer-risk-factors-identified-two-2026a1000ffn May 13, 2026 https://www.medscape.com/c25/p14/digestive-disease-week-ddw-2026-2026a1000c5k Did Hyperglycemia Affect Inavolisib-Efficacy in Patients With Breast Cancer? Megan Brooks https://www.medscape.com/viewarticle/did-hyperglycemia-affect-inavolisib-efficacy-patients-breast-2026a1000fgf May 13, 2026 Efficacy outcomes were numerically higher among patients who experienced inavolisib-associated hyperglycemia, in a post hoc exploratory analysis of the INAVO120 trial. That trial found that patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative advanced breast cancer benefitted from the addition of inavolisib to standard palbociclib and fulvestrant. https://www.medscape.com/c25/p14/esmo-breast-cancer-2026-2026a1000c6q Obesity Drugs Linked to Lower Cancer Risk Edited by Archita Rai https://www.medscape.com/viewarticle/obesity-drugs-linked-lower-cancer-risk-2026a1000fgc May 13, 2026 Only 1 in 4 Eligible Adults Receive Lung Screening Kelsey Mesmer https://www.medscape.com/viewarticle/only-1-4-eligible-adults-receive-lung-screening-2026a1000fee May 13, 2026 Low PSA Alone May Not Fully Predict Survival in Advanced Prostate Cancer Edited by Victoria Stern https://www.medscape.com/viewarticle/low-psa-alone-may-not-fully-predict-survival-advanced-2026a1000few May 13, 2026

The Ivermectin Paradox in Oncology: When a Grain of Science Becomes a ‘Miracle Cure’ Myth Arturo Loaiza-Bonilla, MD, MSEd May 12, 2026

https://www.medscape.com/viewarticle/ivermectin-paradox-oncology-when-grain-science-becomes-2026a1000dyq I’ve started to recognize the cadence of the question before it’s fully asked. A patient or caregiver leans in — often after a long visit about scans, side effects, and the thousand small logistics that cancer demands — and says something like, “Doctor, can I ask you about ivermectin? I heard it’s a cancer cure. If it might help, why wouldn’t we try it?”

Medscape Now! The Changing Demographics of Colorectal Cancer Authors: ​Naseem Bazargan, MPH

https://www.medscape.org/viewarticle/medscape-now-changing-demographics-colorectal-cancer-2026a1000at2?page=1 Colorectal cancer (CRC) ranks as the second most common cause of cancer-related death in the United States, with 158,850 new cases and 55,230 deaths anticipated in 2026.[1] While the overall age-standardized incidence of CRC has declined by approximately 46% from its peak of 66.2 per 100,000 in 1985 to 35.5 per 100,000 in 2019, driven largely by screening uptake and modifiable risk factor reduction, this progress masks a generational divergence.[1,2] Namely, incidence has continued to fall by 2.5% annually among adults aged 65 years and older, while incidence among adults aged 20 to 49 years has increased by approximately 3% annually.[3] Among those aged 50 to 64 years, rates have been stable or rising modestly (+0.4% annually).

Scientists create detailed map of odor receptors

Scientists create detailed map of odor receptors At a Glance Researchers used genetic techniques to map more than 1,000 odor-detecting receptors in mice, revealing a previously unrecognized organizational structure that’s responsible for the sense of smell. The findings could lead to new therapeutic approaches for people who have lost their sense of smell. https://www.nih.gov/news-events/nih-research-matters/scientists-create-detailed-map-odor-receptors

Treating newborns with opioid withdrawal

https://www.nih.gov/news-events/nih-research-matters/treating-newborns-opioid-withdrawal Treating newborns with opioid withdrawal At a Glance A clinical trial showed that giving opioid withdrawal medications based on an infant’s symptoms rather than a set schedule can shorten hospital stays. The findings suggest that as-needed treatment for infant withdrawal may lower the risk of over-treatment.

GLP-1 plus therapy can reduce heavy drinking

https://www.nih.gov/news-events/nih-research-matters/glp-1-plus-therapy-can-reduce-heavy-drinking GLP-1 plus therapy can reduce heavy drinking At a Glance People with alcohol use disorder and obesity drank less when treated with a GLP-1 drug in addition to cognitive behavioral therapy. Findings from the clinical trial suggest GLP-1s could help to treat alcohol use disorder.

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260512-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta

We Sent (Carefully Measured) House Dust to Space to Learn About Human Health May 13, 2026 By: Kate Rimmer and Johanna Camara

https://www.nist.gov/blogs/taking-measure/we-sent-carefully-measured-house-dust-space-learn-about-human-health If you get your cholesterol checked and your doctor sends the sample to two different labs, you should get very similar results. But what if you had to get your cholesterol checked while visiting — or living in — space? How would living in microgravity affect your body’s key indicators, such as cholesterol? It sounds like science fiction, but it’s something scientists are interested in learning about. It’s important to understand, both for a possible future in which people spend more time in space and to see what it can teach us about life here on Earth.

European Scientific Journal ESJ European Scientific Institute, ESI, ESI, Department Member

https://euinstitute.academia.edu/EuropeanScientificJournalESJ Reproducing Neural Network Research Findings via Reverse Engineering: Replication of AlphaGo Zero by Crowdsourced Leela Zero by European Scientific Journal ESJ (example) https://www.academia.edu/167094383/Reproducing_Neural_Network_Research_Findings_via_Reverse_Engineering_Replication_of_AlphaGo_Zero_by_Crowdsourced_Leela_Zero The reproducibility of scientific findings is essential to the integrity of research. The scientific method requires hypotheses to be validated independently by different laboratories. Investigators are expected to provide sufficient information in their publications to permit an objective evaluation of their methods and an independent reproduction of their results. This is particularly true for research supported by public funds, where transparency of both methods and findings represents a return on public investment. Unfortunately, many publications fall short of this standard for various reasons, including a desire to protect intellectual property or national security. The reproducibility of findings is essential in transferring machine learning findings from research into healthcare practice. Fortunately, the internet makes it easier to overcome these limitations by permitting multiple individuals to participate in reproducibility efforts and to crowdsource the reverse engineering of novel software. We present a case study of this capability from neural network research. The success of the crowdsourced project Leela Zero to reverse engineer the findings of AlphaGo Zero exemplifies the ability to reproduce novel results despite the lack of extensive ...

Key Features of PLGD-1 (4 videos)

GEMZ Clinical Trial of Fenfluramine in Patients With CDKL5 Deficiency Disorder by Madaline Spencer| Published on: May 8, 2026

GEMZ Clinical Trial of Fenfluramine in Patients With CDKL5 Deficiency Disorder by Madaline Spencer| Published on: May 8, 2026 Brian Moseley, MD, Senior Medical Director at UCB, discusses the GEMZ clinical trial of fenfluramine in patients with CDKL5 deficiency disorder (CDD). https://checkrare.com/gemz-clinical-trial-of-fenfluramine-in-patients-with-cdkl5-deficiency-disorder/

8-Week Follow-Up Data of RAP-219 for the Treatment of Focal Onset Seizures by Madaline Spencer| Published on: May 11, 2026

8-Week Follow-Up Data of RAP-219 for the Treatment of Focal Onset Seizures by Madaline Spencer| Published on: May 11, 2026 William W. Motley, MD, RAP-219 Program Leader at Rapport Therapeutics, discusses follow-up data of RAP-219 for the treatment of focal onset seizures. https://checkrare.com/8-week-follow-up-data-of-rap-219-for-the-treatment-of-focal-onset-seizures/

Diagnosis and Management of Plasminogen Deficiency by Madaline Spencer| Published on: May 11, 2026

Diagnosis and Management of Plasminogen Deficiency by Madaline Spencer| Published on: May 11, 2026 Amol Sura, MD, Foster Center for Ocular Immunology, Dept of Ophthalmology, Duke University, Durham, North Carolina, discusses the diagnosis and management of plasminogen deficiency, a rare condition in which the eyes are first affected, but it manifests in mucous membranes throughout the body. https://checkrare.com/diagnosis-and-management-of-plasminogen-deficiency/

FDA Expands Indication of Vyvgart (Efgartigimod Alfa) for Adults With Seronegative Myasthenia Gravis by Madaline Spencer| Published on: May 12, 2026

https://checkrare.com/fda-expands-indication-of-vyvgart-efgartigimod-alfa-for-adults-with-seronegative-myasthenia-gravis/ The US Food and Drug Administration (FDA) has approved Vyvgart (efgartigimod alfa) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) for the treatment of adult patients who have anti-MuSK-Ab positive, anti-LRP4-Ab positive, and/or triple seronegative generalized myasthenia gravis (gMG). The medication was previously approved to treat patients with anti-AChR-Ab positive gMG.

Bizengri (Zenocutuzumab) Approved for NRG1 Fusion-Positive Cholangiocarcinoma Under the FDA’s National Priority Voucher Program by Madaline Spencer| Published on: May 13, 2026

https://checkrare.com/bizengri-zenocutuzumab-approved-for-nrg1-fusion-positive-cholangiocarcinoma-under-the-fdas-national-priority-voucher-program/ The US Food and Drug Administration (FDA) has approved Bizengri (zenocutuzumab) for the treatment of adults with NRG1 fusion-positive cholangiocarcinoma. Cholangiocarcinoma is a rare, aggressive cancer that forms in the bile duct. Patients with cholangiocarcinoma are often diagnosed at a later stage when the prognosis is poor. The disease can be classified based on whether the cancer is in the bile duct within the liver (intrahepatic cholangiocarcinoma [iCCA]) or outside the liver (extrahepatic cholangiocarcinoma). NRG1 gene fusions occur in less than 1% of cases and typically occur in patients who are otherwise driver negative, leaving affected patients without approved targeted therapy.

Ecopipam as a Treatment for Tourette Syndrome: Phase 3 Clinical Trial Results by Madaline Spencer| Published on: May 13, 2026

Ecopipam as a Treatment for Tourette Syndrome: Phase 3 Clinical Trial Results by Madaline Spencer| Published on: May 13, 2026 Kinga Tomczak, MD, PhD, Program Director of the Tic Disorders and Tourette Syndrome Program at Boston Children’s Hospital and Assistant Professor of Neurology at Harvard Medical School, discusses phase 3 clinical trial results of ecopipam as a treatment for Tourette syndrome. https://checkrare.com/ecopipam-as-a-treatment-for-tourette-syndrome-phase-3-clinical-trial-results/

Microplastic sorption of personal care products in aquatic environments: mechanisms and key factors Kuok Ho Daniel Tang Volume 3, Issue 1

https://www.academia.edu/journals/academia-environmental-sciences-and-sustainability/articles?source=journal-top-nav Microplastics (MPs) have emerged as dynamic vectors for personal care product (PCP) contaminants, including triclosan, methyl-triclosan, synthetic musks, organic and inorganic UV filters, parabens, caffeine, and other preservatives. Sorption behaviors of MPs are strongly influenced by polymer type, particle size, surface chemistry, aging, and environmental conditions, including pH, salinity, ionic strength, and natural organic matter. Hydrophobicity, hydrogen bonding, π–π interactions, van der Waals forces, and electrostatic effects govern adsorption. Aging and surface oxidation generally enhance MP sorption capacities. For triclosan and methyl-triclosan, hydrophobicity enhances adsorption (24.8–70.8 l g−1 adsorption affinity for methyl-triclosan versus 0.14–0.77 l g−1 for triclosan), while competition/cooperation between compounds alters their individual uptake (antagonist effects on triclosan). Synthetic musks exhibit size- and temperature-dependent adsorption, with polyvinyl chloride generally outperforming polyethylene and polypropylene due to higher surface area and pore volume (0.88–1.60 µg g−1 adsorption capacity for polyvinyl chloride versus 0.860–1.0 µg g−1 for polyethylene). Organic UV filters show multilayer adsorption (5–9100 µg g−1), influenced by polymer type, hydrophobicity, and co-occurring contaminants. Inorganic UV nanoparticles (ZnO, TiO2) interact with MPs via aggregation, dissolution, and reactive oxygen species generation. TiO2 generally shows greater adsorption (up to 72%) than ZnO (16% on polyethylene). Paraben adsorption increases with ester chain length. It is affected by MP polarity, particle size, and aging. Caffeine adsorption is enhanced on aged or humic-acid-enriched MPs (362 µg g−1 on aged polyethylene microplastics versus 237 µg g−1 on pristine ones). It demonstrates limited desorption under pH changes, indicating low bioavailability. Surfactants (anionic, cationic, nonionic) significantly alter MP transport and pollutant uptake by modifying surface charge, adhesion, and hydrophilicity. Adsorption kinetics generally fit pseudo-first- or second-order models, and isotherms align with Freundlich, Langmuir, or Temkin models, reflecting heterogeneous surface interactions. Overall, MPs act as carriers for diverse PCPs, modulating their mobility, persistence, and ecological risk in aquatic systems. Future studies should focus on the combined effects of mixed MPs, surfactants, and co-existing contaminants under realistic environmental conditions to better predict the fate and transport of PCPs. https://www.academia.edu/2997-6006/3/1/10.20935/AcadEnvSci8201

Panel Provides Expert Consensus Guidelines for Adjuvant Radiation for High-Risk Squamous Cell Carcinoma Tara Haelle May 12, 2026 +++ +++

https://www.medscape.com/viewarticle/panel-provides-expert-consensus-guidelines-adjuvant-2026a1000fb8 AUSTIN, Texas — Given that existing adjuvant radiation guidelines for high-risk cutaneous squamous cell carcinoma (cSCC) are inconsistent and based on small, heterogeneous studies, an expert committee laid out recommendations for when to consider radiation after surgery, according to a study presented at the American College of Mohs Surgery (ACMS) Annual Meeting 2026. https://www.medscape.com/c25/p14/american-college-mohs-surgery-acms-annual-meeting-2026-2026a1000bub De-escalation Misses the Mark in Inflammatory Breast Cancer M. Alexander Otto, PA, MMSc https://www.medscape.com/viewarticle/de-escalation-misses-mark-inflammatory-breast-cancer-2026a1000f8f May 12, 2026 Scotland Clears New Bladder Cancer Combination Therapy Edited by Joyani Das https://www.medscape.com/viewarticle/scotland-clears-new-bladder-cancer-combination-therapy-2026a1000fc6 Medscape UK article logo May 12, 2026 QOL Maintained With Giredestrant Combo in Advanced Breast Cancer Megan Brooks https://www.medscape.com/viewarticle/qol-maintained-giredestrant-combo-advanced-breast-cancer-2026a1000fax May 12, 2026 Sigmoidoscopy Cuts Colorectal Cancer Risk in Men Edited by Katie Lennon https://www.medscape.com/viewarticle/sigmoidoscopy-cuts-colorectal-cancer-risk-men-2026a1000f7b May 12, 2026 Nail Unit Squamous Cell Carcinoma: Study Highlights Differences in Invasive vs Noninvasive Cases Edited by Gargi Mukherjee https://www.medscape.com/viewarticle/nail-unit-squamous-cell-carcinoma-study-highlights-2026a1000f80 May 12, 2026

Shared ownership with young people in health research The Lancet Child & Adolescent Health ++... ++

Shared ownership with young people in health research The Lancet Child & Adolescent Health https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00102-1/fulltext?dgcid=raven_jbs_etoc_email Jun 2026 Volume 10Number 6p393-468 https://www.thelancet.com/journals/lanchi/issue/vol10no6/PIIS2352-4642(26)X2004-1 Prevalence estimates of sickle cell disease among children and adolescents in sub-Saharan Africa: a systematic review and modelling analysis Davies Adeloye, PhD FFPHa Send email to D.Adeloye@tees.ac.uk ∙ Asa Auta, PhDb ∙ Boni Maxime Ale, MDc ∙ Jacqueline Y Thompson, PhDd ∙ Prof Igor Rudan, PhD FRSEe,f on behalf of the Global Health Epidemiology Research Group (GHERG) https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00048-9/fulltext?dgcid=raven_jbs_etoc_feature_lanchi Incidence and co-occurrence of six autoimmune diseases in childhood: a population-based cohort study in Norway Prof Ketil Størdal, MD PhDa,b Send email to ketil.stordal@medisin.uio.no ∙ Prof Runar Almaas, MD PhDa,b,c ∙ Prof Helga Sanner, MD PhDd,e ∙ Line Sletner, MD PhDf ∙ Lars C Stene, PhD https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00008-8/abstract?dgcid=raven_jbs_etoc_feature_lanchi

Researchers develop innovative model for risk assessment for hypertrophic cardiomyopathy

Researchers develop innovative model for risk assessment for hypertrophic cardiomyopathy NIH-funded study incorporates new measures to better predict outcomes in chronic heart condition. Findings from a study supported in part by the National Institutes of Health (NIH) have identified a new model for predicting outcomes for hypertrophic cardiomyopathy (HCM), a heart condition with a prevalence of 1 in 500 people and a frequent cause of sudden cardiac death. Specifically, the findings demonstrate that incorporating prospective data including clinical history, imaging, and blood biomarker data into risk assessment can improve prediction of adverse cardiac events in people with HCM. https://www.nih.gov/news-events/news-releases/researchers-develop-innovative-model-risk-assessment-hypertrophic-cardiomyopathy U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Monday, May 11, 2026 CONTACT: NIH Office of Communications, RESEARCHERS DEVELOP INNOVATIVE MODEL FOR RISK ASSESSMENT FOR HYPERTROPHIC CARDIOMYOPATHY NIH-funded study incorporates new measures to better predict outcomes in chronic heart condition Findings from a study supported in part by the National Institutes of Health (NIH) have identified a new model for predicting outcomes for hypertrophic cardiomyopathy (HCM), a heart condition with a prevalence of 1 in 500 people and a frequent cause of sudden cardiac death. Specifically, the findings demonstrate that incorporating prospective data including clinical history, imaging, and blood biomarker data into risk assessment can improve prediction of adverse cardiac events in people with HCM. The large, international study, called the Hypertrophic Cardiomyopathy Registry, was initially funded by NIH’s National Heart, Lung, and Blood Institute (NHLBI). The findings were published in JAMA. “Current risk prediction guidelines for hypertrophic cardiomyopathy are imperfect, as they predict only sudden cardiac death, and not heart failure or other fatal and nonfatal cardiac adverse events,” said Christopher Kramer, M.D., a principal investigator of the study and cardiologist at the Heart and Vascular Center of the University of Virginia Health System. “This study is a major advance in that it provides evidence that incorporating these additional assessment methods better predicts risk of adverse outcomes.” Hypertrophic cardiomyopathy occurs when the heart muscle becomes larger and thicker than normal, which can block the outflow of the left ventricle, leading to heart failure symptoms, and can lead to rapid, life-threatening heart rhythm abnormalities. It is commonly inherited, and many people with the condition are asymptomatic, pointing toward the need for better risk prediction. The researchers in this study wanted to see if integrating new methods into assessment—including a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced cardiac magnetic resonance imaging (MRI)—could more accurately predict adverse events such as sudden cardiac death, heart failure, nonfatal arrythmias, and the need for device implantation or heart transplantation. The study enrolled close to 2,700 patients with HCM in North America and Europe at 44 sites that had expertise in HCM and cardiac imaging. The researchers collected medical history, blood tests, and cardiac imaging, and followed the study participants for seven years on average. Through this work, they determined that several predictors such as scarring, weight, and function of the heart muscle seen by imaging; history of heart failure; and higher levels of a blood biomarker (NTproBNP), were associated with fatal and nonfatal cardiac events. Sudden cardiac death outcomes were predicted by determining structure and function of the left ventricle by cardiac MRI and the blood biomarker tests. In short, they showed that integrating these study methods into risk assessment gave fuller and more accurate predictions of adverse events. “This study provides strong evidence for incorporating cardiac MRI and blood biomarkers into risk prediction for people with HCM,” said David Goff, M.D., Ph.D., acting director of NHLBI. “This condition has significant morbidity and mortality, and advances in risk prediction like this have the potential to change disease management and improve outcomes for patients.” About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at: U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Monday, May 11, 2026 CONTACT: NIH Office of Communications, RESEARCHERS DEVELOP INNOVATIVE MODEL FOR RISK ASSESSMENT FOR HYPERTROPHIC CARDIOMYOPATHY NIH-funded study incorporates new measures to better predict outcomes in chronic heart condition Findings from a study supported in part by the National Institutes of Health (NIH) have identified a new model for predicting outcomes for hypertrophic cardiomyopathy (HCM), a heart condition with a prevalence of 1 in 500 people and a frequent cause of sudden cardiac death. Specifically, the findings demonstrate that incorporating prospective data including clinical history, imaging, and blood biomarker data into risk assessment can improve prediction of adverse cardiac events in people with HCM. The large, international study, called the Hypertrophic Cardiomyopathy Registry, was initially funded by NIH’s National Heart, Lung, and Blood Institute (NHLBI). The findings were published in JAMA. “Current risk prediction guidelines for hypertrophic cardiomyopathy are imperfect, as they predict only sudden cardiac death, and not heart failure or other fatal and nonfatal cardiac adverse events,” said Christopher Kramer, M.D., a principal investigator of the study and cardiologist at the Heart and Vascular Center of the University of Virginia Health System. “This study is a major advance in that it provides evidence that incorporating these additional assessment methods better predicts risk of adverse outcomes.” Hypertrophic cardiomyopathy occurs when the heart muscle becomes larger and thicker than normal, which can block the outflow of the left ventricle, leading to heart failure symptoms, and can lead to rapid, life-threatening heart rhythm abnormalities. It is commonly inherited, and many people with the condition are asymptomatic, pointing toward the need for better risk prediction. The researchers in this study wanted to see if integrating new methods into assessment—including a health history questionnaire, blood sampling for biomarkers and genotyping, and contrast-enhanced cardiac magnetic resonance imaging (MRI)—could more accurately predict adverse events such as sudden cardiac death, heart failure, nonfatal arrythmias, and the need for device implantation or heart transplantation. The study enrolled close to 2,700 patients with HCM in North America and Europe at 44 sites that had expertise in HCM and cardiac imaging. The researchers collected medical history, blood tests, and cardiac imaging, and followed the study participants for seven years on average. Through this work, they determined that several predictors such as scarring, weight, and function of the heart muscle seen by imaging; history of heart failure; and higher levels of a blood biomarker (NTproBNP), were associated with fatal and nonfatal cardiac events. Sudden cardiac death outcomes were predicted by determining structure and function of the left ventricle by cardiac MRI and the blood biomarker tests. In short, they showed that integrating these study methods into risk assessment gave fuller and more accurate predictions of adverse events. “This study provides strong evidence for incorporating cardiac MRI and blood biomarkers into risk prediction for people with HCM,” said David Goff, M.D., Ph.D., acting director of NHLBI. “This condition has significant morbidity and mortality, and advances in risk prediction like this have the potential to change disease management and improve outcomes for patients.” About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office ### This NIH News Release is available online at:

The sleep paradox: why do humans sleep so little when we need it so much? By Nathaniel J. Dominy

The sleep paradox: why do humans sleep so little when we need it so much? A new book brings together ethnography, neurobiology and primatology to argue that how much our species sleeps is an evolutionary trade-off, with lessons for how each of us can sleep better. By Nathaniel J. Dominy https://www.nature.com/articles/d41586-026-01478-9?utm_source=Live+Audience&utm_campaign=677edada85-nature-briefing-daily-20260511&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Why humans sleep so little On the basis of the sleeping habits of closely related animals, biological anthropologist David Samson estimates that humans require roughly 2.5 hours more sleep than we tend to get each day. This “human sleep paradox” is the focus of his book, The Sleepless Ape. Using ethnography, neurobiology and primatology, Samson argues that the amount of sleep our species gets reflects an evolutionary trade-off. Short, high-quality bouts of sleep helped our ground-sleeping ancestors to stay alert to predators, with the bonus of more waking hours for social interaction and learning — something that reshaped the trajectory of our evolution.

NIH-funded study maps human pancreatic islet cells, offering new clues to diabetes risk

NIH-funded study maps human pancreatic islet cells, offering new clues to diabetes risk Comprehensive characterization of islet cells facilitated by national organ donation program. https://www.nih.gov/news-events/news-releases/nih-funded-study-maps-human-pancreatic-islet-cells-offering-new-clues-diabetes-risk Isolated islets showing cell nuclei (blue) and three main endocrine cell types: insulin-producing beta cells (green), glucagon-producing alpha cells (red), and somatostatin-producing delta cells (white). A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Tuesday, May 12, 2026 CONTACT: NIH Office of Communications, NIH-FUNDED STUDY MAPS HUMAN PANCREATIC ISLET CELLS, OFFERING NEW CLUES TO DIABETES RISK Comprehensive characterization of islet cells facilitated by national organ donation program A National Institutes of Health (NIH)-funded study has identified key differences in human pancreatic islet cells that may help explain why some people are more likely to develop diabetes. Researchers found that the mix of hormone-producing cells in the pancreas varies widely from person to person, and that variation plays a central role in how the body regulates blood sugar. Researchers analyzed islets from 299 donors collected through the NIH-funded Integrated Islet Distribution Program (IIDP), at City of Hope in Duarte, California, the largest source of human islets for research in the country. Scientists say the dataset will help clarify how genetic and biological factors combine to influence diabetes risk. “This level of characterization across so many donors has not been done in the past,” said Albert J. Hwa, Ph.D., program director at NIH’s National Institute of Diabetes and Kidney Diseases (NIDDK). “Collection and analysis of this rich trove of data should enable better understanding of how multiple factors come together to contribute to the risk of developing diabetes.” The study analyzed pancreatic islets — clusters of cells that regulate blood glucose by releasing hormones. These include: --Alpha cells, which produce glucagon to raise blood sugar --Beta cells, which produce insulin to lower blood sugar --Delta cells, which produce somatostatin to regulate both The IIDP team developed the infrastructure for managing and coordinating human pancreatic islet isolation, while maximizing islet yield, viability and purity. The donor group represented in this study reflects a diverse range of race, ethnicity, sex, age and body mass index measurements. “The composition of the organ donor pool is highly reflective of the population of the United States,” said study co-lead author Carmella Evans-Molina, M.D., Ph.D., director of the Indiana Diabetes Research Center at Indiana University School of Medicine and IIDP co-principal investigator. “This attribute of the study population is important for understanding differences in islet function between people of different backgrounds.” The study involved a deep dive into islet cell function that is linked to donor traits associated with observable characteristics, or phenotype, such as sex, race and ethnicity, as well as genetic information, or genotype, including predicted ancestry and genetic risk for both type 1 and type 2 diabetes. On average, islets were comprised of 34% alpha cells, 58% beta cells and 8% delta cells. However, the researchers detected broad variability in the percentage of alpha and beta cells in the study population, and lower but significant variation in the percentage of delta cells. Since each cell has a particular role in sugar metabolism, this variability has complex effects that inform future investigation. The findings highlight that islet cell composition, rather than the physical size and shape of islets, is a key factor in regulating hormone release. The team found that the makeup of pancreatic islets plays a major role in how effectively they release insulin and glucagon — key hormones that regulate blood glucose. Islets with a higher proportion of insulin-producing beta cells showed stronger insulin secretion in response to various stimuli, while higher levels of alpha and delta cells were generally linked to reduced insulin output. The researchers observed that cells derived from female donors tended to have a higher percentage of alpha cells and a lower percentage of beta cells. Their findings also suggested differences in beta cell proportions across ancestry groups. In addition, the researchers found that islet hormone secretion is affected by donor traits, such as sex, race and ethnicity and their genetic makeup, including ancestry predicted from genetic testing and genetic risk for type 2 diabetes. Combined, the findings of the study have significant implications for understanding the factors that may predispose people to diabetes. “This study is the tip of the iceberg,” said Dr. Evans-Molina. “We hope this dataset becomes useful to the entire diabetes research community and that researchers use it to answer questions about the genotype-phenotype correlation within these data.” Co-authors of the study include IIDP founder and principal investigator Joyce Niland, Ph.D.; HIPP director Marcela Brissova, Ph.D. and HIPP scientist Yasminye Pettway, Ph.D.; and HIGI director Anna Gloyn, D.Phil. This research was supported in part by NIDDK and the National Institute of General Medical Sciences, through grants UC4DK098085, U24DK098085, F30DK134041, R01DK129469, T32GM007347 and T32GM152284. The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition, and obesity; and kidney, urologic, and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see https://www.niddk.nih.gov/. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office --- REFERENCES: C Evans-Molina YD Pettway, DC Saybders, et al. Heterogeneous endocrine cell composition defines human islet functional phenotypes. Nature Communications. DOI: 10.1038/s41467-026-70689-5. ### This NIH News Release is available online at:

You cannot understand biology by killing it Written byBree Foster, PhD

You cannot understand biology by killing it Drug discovery still relies on destroying cells to understand how they respond, but new real-time measurement approaches are beginning to reveal biology in motion rather than in snapshots. Written byBree Foster, PhD https://www.drugdiscoverynews.com/you-cannot-understand-biology-by-killing-it-17159 Modern drug discovery is built on a paradox. To learn how living systems respond to intervention, we routinely destroy them. Cells are lysed, fixed, stained, sequenced, averaged, and reconstructed after the fact. This gives us a snapshot of what the cells were like before and after, but tells us very little about what happened in between.

A new marketplace wants to rescue shelved cell and gene therapies . Written byAndrea Corona

A new marketplace wants to rescue shelved cell and gene therapies CGTxchange pairs an AI-enabled evaluation platform with ASGCT's global network to connect deprioritized rare disease programs with new sponsors and investors. Written byAndrea Corona https://www.drugdiscoverynews.com/a-new-marketplace-wants-to-rescue-shelved-cell-and-gene-therapies-17168 Hundreds of cell and gene therapies (CGTs) that showed clinical promise have been shelved in recent years — not because they failed patients, but because they failed to meet traditional commercial return expectations. A new joint venture announced January 7, 2026, is attempting to create an alternative pathway for those programs.

Immunotherapy for Non-Muscle-Invasive Bladder Cancer: Expert Takeaways From the Latest Updates Authors: Bernadett Szabados, MD; Maria De Santis, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af?page=1&src=mkmcmr_driv_stan_mscpedu_260511-OUS-HONC-immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af-cta&uac=148436CN

Tenosynovial Giant Cell Tumor in Focus: Quickfire Insights From Multidisciplinary Experts Authors: Hans Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD

https://www.medscape.org/viewarticle/tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py?page=1&src=mkmcmr_driv_stan_mscpedu_260512-OUS-HONC-tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py-cta&uac=148436CN

Therapeutic Evolution in mHSPC: Analyzing Emerging Combinations and Outcomes Authors: Rana R. McKay, MD, FASCO; Alicia K. Morgans, MD, MPH, FASCO; David Morris, MD, FACS

https://www.medscape.org/viewarticle/therapeutic-evolution-mhspc-analyzing-emerging-combinations-2026a100087o?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260511-OUS-HONC-therapeutic-evolution-mhspc-analyzing-emerging-combinations-2026a100087o-cta

RAS-Targeted Strategies in Pancreatic Cancer: Progress and Future Directions Authors: Brian M. Wolpin, MD, MPH; Eileen M. O’Reilly, MD, FASCO; Zev A. Wainberg, MD

https://www.medscape.org/viewarticle/ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c?page=1&src=mkmcmr_driv_stan_mscpedu_260511-OUS-HONC-ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c-cta&uac=148436CN

Meeting Highlights: April Office of AIDS Research Advisory Council meeting +++

Highlights: April 2026 NIH Office of AIDS Research Advisory Council Meeting Advancing clinical trials network strategy, navigating NIH funding and peer review changes, and health disparities research The National Institutes of Health (NIH) Office of AIDS Research Advisory Council (OARAC) convened its 71st meeting virtually on April 13. OARAC provides advice to the NIH Office of AIDS Research (OAR) on the planning, coordination, and evaluation of research and other HIV-related activities conducted or supported by NIH. https://www.oar.nih.gov/about/oarac/previous-meetings/april-2026 Previous OAR Advisory Council Meetings OARAC meetings are typically held three times per year. These meetings are open to the public, with limited exceptions, and public comments are welcome. To submit a comment for an upcoming OARAC meeting, please send it to OARACinfo@nih.gov. Find links below to previous meeting videocasts, minutes, and summaries. https://www.oar.nih.gov/about/oarac/previous-meetings Blog: Stay Current With News and Updates https://www.hiv.gov/blog?utm_source=newsletter&utm_medium=email&utm_campaign=blog

‘Too Good to Be True?’ GLP-1s and Breast Cancer Survival F. Perry Wilson, MD, MSCE May 11, 2026

https://www.medscape.com/viewarticle/too-good-be-true-glp-1s-and-breast-cancer-survival-2026a1000f4e Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr F. Perry Wilson from the Yale School of Medicine.

Recurrent UTIs Within 6 Months May Signal Cancer Risk Paolo Spriano, MD Medscape UK May 11, 2026

https://www.medscape.com/viewarticle/recurrent-utis-within-6-months-may-signal-cancer-risk-2026a1000ezu?ecd=wnl_edit_tpal_etid8335039&uac=148436CN&impID=8335039 Cancer diagnosis most often follows symptom onset and typically occurs in primary care settings. Improving the ability of clinicians to identify individuals who require urgent investigation into suspected cancer could support earlier diagnosis and improve outcomes. However, correct diagnosis remains challenging because general practitioners must manage symptoms early in their course, often in the presence of multiple evolving clinical features.

OCMO Webinar - Informed Care in Psychiatric Medication Use and Withdrawal Fecha y hora 3 jun 2026 03:00 p. m.

https://zoom.us/webinar/register/WN_A_RgmmwtTy2lY22iGnmvoA?utm_source=SAMHSA&utm_campaign=a9ce11e3ce-EMAIL_CAMPAIGN_2026_05_11_01_40&utm_medium=email&utm_term=0_-a9ce11e3ce-167840245#/registration CME/CEU Credits Available. This activity is designated for 1.0 CEUs or 1.0 AMA PRA Category Credits™. SAMHSA’s Office of the Chief Medical Officer will host a webinar titled “Informed Care in Psychiatric Medication Use and Withdrawal”. The event will feature Matthew Rudorfer, MD; Mark Horowitz, MD, PhD; and Laura Delano. The webinar will explore a range of psychiatric treatment options and strategies to support fully informed care, including understanding benefits, potential risks, dependence, and withdrawal considerations. Presenters will discuss emerging perspectives in the field, highlight current evidence, and examine approaches that promote collaborative decision-making between providers and patients. Following the presentations, attendees will have the opportunity to participate in a moderated question-and-answer segment. Questions will be addressed in the order received, with priority given to those submitted during registration. The webinar is open to all, but registration is required. Presenters: Matthew Rudorfer, MD, is Chief of the Psychopharmacology, Somatic, and Integrated Treatments Research Program in the Treatment and Preventive Interventions Research Branch within the Division of Services and Intervention Research at the National Institute of Mental Health. Mark Horowitz, MD, PhD, is an Associate Professor of Psychiatry at the University of Adelaide, a Visiting Lecturer in Psychopharmacology at King’s College London, and the lead of the National Psychotropic Deprescribing Clinic within the United Kingdom’s National Health Service. Laura Delano is an author, speaker, and consultant, and the founder of Inner Compass Initiative, a nonprofit organization that supports informed decision-making about psychiatric drugs and promotes non-medicalized approaches to human distress. In support of improving patient care, the Substance Abuse and Mental Health Services Administration is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide interprofessional collaborative continuing education (IPCE) activities for the healthcare team. IPCE activity credits are accepted as CME for medical practitioners, and CE for dieticians, nurses, pharmacists, physician associates/physician assistants, psychologists, and social workers. The activity was planned by and for the healthcare team. Please note: Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. As a Jointly Accredited Organization, the Substance Abuse and Mental Health Services Administration is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 CEU continuing education credits. Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. The views, opinions, and content expressed in this presentation do not necessarily reflect the views, opinions, or policies of the Substance Abuse and Mental Health Services Administration or the U.S. Department of Health and Human Services (HHS). Questions may be directed to SAMHSAStateTA@JBSInternational.com

Coronary Disease Risk in Asymptomatic Patients with Left Ventricular Moderate Dilatation By European Scientific Journal ESJ

https://www.academia.edu/167018571/Coronary_Disease_Risk_in_Asymptomatic_Patients_with_Left_Ventricular_Moderate_Dilatation?email_work_card=title Goal of the Study is to assess the risk of coronary disease of asymptomatic ischemia in patients with left ventricular moderate dilatation. Methods: The work was based on the results of investigation of 185patients with left ventricular moderate dilatation, aged 35-55 years from the "Tbilisi Heart and Vascular Clinic" contingent. Among them, there are 159 men and 26 women. Results: Patients who suffer from left ventricular moderate dilatation and don't expose typical symptom of ischemia possibly are in risk of carrying damaged coronary artery. the LV moderate dilatation of the left ventricle can be used for primary diagnosing of silent ischemia. Sensitivity-0.867(95%CI:0.806-0.927); Specificity-0.800(95%CI:0.703-0.897); Prognostic value of positive results; 0.889(95%CI:0.832-0.946); Prognostic value of negative results-0.765(95%CI:0.664-0.866); diagnostic value-0.843(95%CI:0.791-0.896). Conclusions: In patients with silent ischemia, the coronary disease predictors are: left ventricular moderate dilatation, male gender, dyslipidemia, arterial hypertension, smoking, positive treadmill test, ischemic disease in 1st degree relatives, low tolerance to treadmill test. Thus, ... https://euinstitute.academia.edu/EuropeanScientificJournalESJ

Synthetic biology under debate: science and ethics meet to define the human future By Bioethics Observatory Published On: April 23rd, 2026

Synthetic biology under debate: science and ethics meet to define the human future By Bioethics Observatory Published On: April 23rd, 2026 https://bioethicsobservatory.org/2026/04/synthetic-biology-under-debate-science-and-ethics-meet-to-define-the-human-future/48631/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet International experts analyzed at the Catholic University of Valencia the possibilities, limits and bioethical challenges posed by gene editing and the creation of organoids. On April 20, the Bioethics Observatory at the Catholic University of Valencia (UCV) held its annual conference titled “Synthetic Biology and the Future of Humanity: Possibilities, Limits, and Bioethical Challenges”.

Uruguay regulates euthanasia: key aspects of the new legal framework and its ethical implications By Bioethics Observatory Published On: May 11th, 2026

Uruguay regulates euthanasia: key aspects of the new legal framework and its ethical implications By Bioethics Observatory Published On: May 11th, 2026 https://bioethicsobservatory.org/2026/05/uruguay-regulates-euthanasia-key-aspects-of-the-new-legal-framework-and-its-ethical-implications/48705/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet Recently, the President of Uruguay, Yamandú Orsi, signed a decree regulating Law No. 20.431, which regulates euthanasia and the right to a dignified death, recognizing the possibility for individuals to request it in accordance with the provisions of the law.

The International Olympic Committee bans transgender women from competing in women’s category By Bioethics Observatory Published On: April 28th, 2026

The International Olympic Committee bans transgender women from competing in women’s category By Bioethics Observatory Published On: April 28th, 2026 https://bioethicsobservatory.org/2026/04/the-international-olympic-committee-bans-transgender-women-from-competing-in-womens-category/48688/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet On March 26, the IOC published a document outlining its new policies regarding the participation of transgender women in Olympic competitions. These new regulations will apply starting with the Los Angeles Olympic Games in 2028 and are not retroactive.

Bioethical issues in anonymous gamete donation: the genetic risk of assisted human reproduction By Bioethics Observatory Published On: April 22nd, 2026

Bioethical issues in anonymous gamete donation: the genetic risk of assisted human reproduction By Bioethics Observatory Published On: April 22nd, 2026 https://bioethicsobservatory.org/2026/04/bioethical-issues-in-anonymous-gamete-donation-the-genetic-risk-of-assisted-human-reproduction/48617/?utm_source=mailpoet&utm_medium=email&utm_source_platform=mailpoet Gamete donation in assisted human reproduction is a topic that generates considerable debate in bioethics, centered mainly on the discussion of how to accommodate the wishes of the intended parents while respecting the rights of the children, who should always remain the primary focus in the application of these technologies.

Pathways to publication in diabetes Tuesday, 19/05/2026 · 06:00 Atlantic Time (Canada) (GMT -3:00) Cost: Free

https://www.bigmarker.com/lancet-webinars/pathways-to-publication-in-diabetes?utm_bmcr_source=hubspot_email_reg2_publishingexcellence_p2pd&_hsmi=418088165&_hsenc=p2ANqtz-8y7MQkmy2DKSUTdWCCanEeEgwWsMrS1-J8AuGHWBnhoAbaQp3rgDUWAGXFVsLneRtj8_NtraRXTv1SQJKPAygp98ROjQ&hsCtaAttrib=209864303118 In this session, expert editors from across The Lancet Group will share practical guidance to help you navigate the publication process and find the best home for your diabetes research, whether you choose to submit your paper to The Lancet or one of the Lancet specialty, Regional Health, or Discovery Science journals. Hear directly from our editorial team: Helena Wang, Asia Executive Editor, The Lancet, China Callam Davidson, Senior Editor and Diabetes Ambassador, The Lancet, UK Marta Koch, Editor-in-Chief, The Lancet Diabetes & Endocrinology, UK Shalini Garg, Editor-in-Chief, The Lancet Regional Health - Southeast Asia, India Charlotte Rowbottom, Deputy Editor, eClinicalMedicine, UK During the webinar, you will: Learn about the different Lancet publication options available for diabetes content. Understand how our article transfer service works to find the best fit for your work. Gain valuable insights from our editorial teams on optimising your manuscript for success. You will also have the opportunity to ask your questions during a live Q&A with our editors.

Editorial Putting rural health first in the fuel crisis The Lancet Regional Health – Western Pacific +++ +...

Mental health systems in Pacific island countries and territories: a scoping review of current evidence Jialing Lina,t Send email to jialing.lin@unsw.edu.au ∙ Xinrui Weia,b,t ∙ Peixin Hanc ∙ Tinghsuan Hsud ∙ Jiaying Sune ∙ Carey Marrf ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00060-X/fulltext?dgcid=hubspot_update_feature_updatealerts_lanwpc&utm_campaign=update-lanwpc&utm_medium=email&_hsenc=p2ANqtz--o2GqMUNn2-bAsgpSlzu8xlzfQIZACmYD_z2ndWbb71tYYqKuGwKMGylEBXYYS8F8ogPKUV0MYqK7Y5_Oy-9UTJyQTpw&_hsmi=418096106&utm_content=417891082&utm_source=hs_email G6PD deficiency in Indonesia: a systematic review and update of prevalence and variant maps in the context of malaria elimination Arkasha Sadhewaa Send email to arkasha.sadhewa@menzies.edu.au ∙ Lydia Visita Panggalob ∙ Illene Nanineb ∙ Ihsan Fadilahc,d ∙ Jontari Hutagalunge ∙ Enny Kenangalemf ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00044-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanwpc&utm_campaign=update-lanwpc&utm_medium=email&_hsenc=p2ANqtz-8208OgfP3ipvri86dv2ytxroFMRL4Y8WVL-MiOq-GiqmnYbTNBp6xh90RlG_gqFSLcuAZLe3PkA2G5H76UKh3YY-7zEQ&_hsmi=418096106&utm_content=417891082&utm_source=hs_email Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study Yongfeng Yua ∙ Qisen Guob ∙ Yongchang Zhangc ∙ Jian Fangd ∙ Diansheng Zhonge ∙ Baogang Liuf ∙ et al. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00038-6/fulltext?dgcid=hubspot_update_feature_updatealerts_lanwpc&utm_campaign=update-lanwpc&utm_medium=email&_hsenc=p2ANqtz-9yRE0bEEXAvrVFx-VuqooLlcgjok7P-7b9LMDCNzociNnMOyfolgEJLOSzmzBKSdczvb52HxDpqAmc0w7d2Tv3tIWUlg&_hsmi=418096106&utm_content=417891082&utm_source=hs_email Editorial Putting rural health first in the fuel crisis The Lancet Regional Health – Western Pacific https://www.thelancet.com/journals/lanwpc/issue/vol69nonull/PIIS2666-6065(26)X2002-8

Mental health at the heart of haematology The Lancet Haematology ++... ++

Mental health at the heart of haematology The Lancet Haematology https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00103-1/fulltext?dgcid=hubspot_update_feature_updatealerts_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsenc=p2ANqtz-92YnmcMUuop3WTnuhyw3wgOEm5OouVQPfp1cvAeyIZJgeIXOUn577ZDPd2y3H7nTHlmW_S6Ai7EKWVMCjRqqZEY2EO_w&_hsmi=418093480&utm_content=417887741&utm_source=hs_email May 2026 Volume 13Number 5e267-e352 https://www.thelancet.com/journals/lanhae/issue/vol13no5/PIIS2352-3026(26)X2004-X Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network Yonatan Edel, MDa,b,* ∙ Penelope E Stein, FRCPathc,* Send email to p.stein@nhs.net ∙ Hassan Kawtharany, MDd,e ∙ Aasne K Aarsand, MDf,g ∙ Prof Michael Badminton, FRCPathh ∙ Prof Manisha C Balwani, MDi ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00044-X/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-90gfx4HRCupVtVa16qATrT39SgEC8P7VIMMxcKXaGI9dlolNoExt3jdJtrvmESdzT4CjIEvtNJ6jHXQ7AwNGsSsMoDzA&_hsmi=418093480&utm_content=417887741&utm_source=hs_email Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial Prof M Lia Palomba, MDa,† Send email to palombam@mskcc.org ∙ Manish R Patel, MDb,† ∙ Toby A Eyre, MBChB MDc ∙ Prof Wojciech Jurczak, MD PhDd ∙ David Lewis, MBChB PhDe ∙ Thomas Gastinne, MDf ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00037-2/abstract?utm_campaign=update-lanhae&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanhae&_hsenc=p2ANqtz-_NDe07fzhSLDtUeCCVR8mItl5USxda6fyIhwxtNUjE8eMmH9mfg3i-TFzGq4oi3D4-f4iAmyZpUQg977380nCYKk7NBg&_hsmi=418093480&utm_content=417887741&utm_source=hs_email

Technological mourning after AI updates: mental health and well-being in the GPT-4o/GPT-5 transition Véronique Donard* [1] , José Carlos Ribeiro [2]

https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8256 Introduction: While large language models (LLMs) are increasingly experienced as relational partners, limited empirical research exists regarding how users emotionally experience abrupt changes in these systems. This study investigates the psychological, affective, and cognitive impacts of the temporary removal of GPT-4o and its replacement by GPT-5 in August 2025, mapping the consequences for user well-being through the exploration of the emerging phenomenon of technological mourning. We propose the concept of “technological mourning,” defined as the affective response to the perceived loss of a digital partner. The framework draws on theory of individuation, second-order cybernetics, and distributed cognition to interpret user reactions as signals of disturbances within human–AI systems. https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav

Type 1 Plasminogen Deficiency Overview by Madaline Spencer| Published on: Mar 13, 2026

Type 1 Plasminogen Deficiency Overview by Madaline Spencer| Published on: Mar 13, 2026 Amy Shapiro, MD, a pediatric hematologist and the Medical Director and CEO of the Indiana Hemophilia and Thrombosis Center in Indianapolis, provides CheckRare an overview on type 1 plasminogen deficiency (PLGD-1). https://checkrare.com/type-1-plasminogen-deficiency-overview/

8-Week Follow-Up Data of RAP-219 for the Treatment of Focal Onset Seizures by Madaline Spencer| Published on: May 11, 2026

8-Week Follow-Up Data of RAP-219 for the Treatment of Focal Onset Seizures by Madaline Spencer| Published on: May 11, 2026 William W. Motley, MD, RAP-219 Program Leader at Rapport Therapeutics, discusses follow-up data of RAP-219 for the treatment of focal onset seizures. https://checkrare.com/8-week-follow-up-data-of-rap-219-for-the-treatment-of-focal-onset-seizures/

MHRA Approves New Prophylactic for Rare Swelling Disorder Edited by Zeel Mehta Medscape UK May 11, 2026

https://www.medscape.com/viewarticle/mhra-approves-new-prophylactic-rare-swelling-disorder-2026a1000f05 The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Dawnzera (donidalorsen, Otsuka Pharmaceutical Netherlands B.V.) for the prevention of swelling attacks in patients aged 12 years or older with hereditary angioedema. The approval was granted through the International Recognition Procedure.

Zenocutuzumab OK’d for NRG1 Fusion-Positive Cholangiocarcinoma M. Alexander Otto, PA, MMSc May 11, 2026

https://www.medscape.com/viewarticle/zenocutuzumab-okd-nrg1-fusion-positive-cholangiocarcinoma-2026a1000f2r The FDA has approved zenocutuzumab (BIZENGRI, Partner Therapeutics) for adults with advanced, unresectable, or metastatic cholangiocarcinoma harboring an NRG1 gene fusion following progression on or after prior systemic therapy.

Patient-Reported Data Strengthen Case for Dato-DXd in First-Line TNBC Megan Brooks May 11, 2026

https://www.medscape.com/viewarticle/patient-reported-data-strengthen-case-dato-dxd-first-line-2026a1000f34 First-line datopotamab deruxtecan (Dato-DXd) not only improved survival outcomes vs chemotherapy but also delivered sustained quality-of-life benefits (QoL) for patients with locally recurrent, inoperable, or metastatic triple-negative breast cancer (TNBC) who were not candidates for immunotherapy in the TROPION-Breast02 study. https://www.medscape.com/c25/p14/esmo-breast-cancer-2026-2026a1000c6q

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC Liam Davenport May 11, 2026

https://www.medscape.com/viewarticle/no-survival-benefit-seen-adjuvant-atezolizumab-tnbc-2026a1000f20 Adding atezolizumab immunotherapy to capecitabine for the adjuvant treatment of triple-negative breast cancer (TNBC) in patients with residual disease after neoadjuvant chemotherapy does not offer a significant survival benefit, suggested a Korean trial. There was nevertheless a numerical improvement seen in both invasive disease-free and overall survival with atezolizumab plus capecitabine vs capecitabine alone, reaching a trend toward a benefit in patients with tumors positive for PD-L1 expression.

FDA Seeks Advice on Researching the Effects of Drugs Taken During Pregnancy Kerry Dooley Young May 11, 2026

https://www.medscape.com/viewarticle/fda-seeks-advice-researching-effects-drugs-taken-during-2026a1000f2k US regulators are seeking to expand the knowledge base about potential side effects of medicines when taken during pregnancy because clinicians and their patients have long been concerned about the lack of information in this field. Speaking on May 8 at a workshop held by the FDA, Kavita Shah Arora, MD, MBE, MS, recalled a recent conversation with a patient who was weighing whether to take a certain medication while pregnant.

Mental Health Conditions Can Predict Cancer Risk, UK Biobank Study Reveals Edited by Vineeta Teotia Medscape UK May 11, 2026

https://www.medscape.com/viewarticle/mental-health-conditions-can-predict-cancer-risk-uk-biobank-2026a1000etm Mental health conditions (MHCs) such as depression, anxiety, and bipolar disorders were associated with increased risks for overall and site-specific cancers, according to a population-based study.

False Positive mt-sDNA Tests Linked to Higher Rate of Aerodigestive Cancers Damian McNamara, MA May 11, 2026

https://www.medscape.com/viewarticle/false-positive-mt-sdna-tests-linked-higher-rate-2026a1000f3f CHICAGO — Once a multi-target stool DNA (mt-sDNA) test is identified as a false positive, it is often considered reassuring for patients and providers concerned about colorectal cancer. However, new research links these false positives to a small but significant increase in head and neck, lung, and gastric aerodigestive cancers, pointing to a need to further evaluate these patients.

FDA Advisors Split on Regimens for Breast, Prostate Cancers Sharon Worcester May 11, 2026

https://www.medscape.com/viewarticle/fda-advisors-split-regimens-breast-prostate-cancers-2026a1000f3j In its first meeting in 9 months, the FDA’s Oncologic Drugs Advisory Committee (ODAC) backed a novel regimen for certain patients with prostate cancer but voted against recommending a new treatment approach with an investigational drug for breast cancer.

Angiolipoleiomyoma Masquerading as Leiomyoma in a Woman Wolfgang Paik May 11, 2026

https://www.medscape.com/viewarticle/angiolipoleiomyoma-masquerading-leiomyoma-woman-2026a1000f23 A 45-year-old woman with a 2-year history of vaginal foreign body sensation was found to have a large posterior vaginal wall mass; an initial biopsy suggested a leiomyoma, but surgical excision revealed an angiolipoleiomyoma, highlighting the diagnostic challenges with heterogeneous pelvic tumors. The case report by gynecologist Diana Mendoza-Arcique Sr and colleagues from the Hospital Regional “Elvia Carrillo Puerto,” Institute for Social Security and Services for State Workers, Mérida, Mexico, documents a rare benign mesenchymal tumor.

Navigating the HER2 Spectrum in Breast Cancer: Evolving Diagnostic Paradigms for Clinical Excellence Authors: Sara M. Tolaney, MD, MPH; Frédérique Penault-Llorca, MD; Giuseppe Curigliano, MD, PhD

https://www.medscape.org/viewarticle/navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea?page=1&src=mkmcmr_driv_stan_mscpedu_260511-OUS-HONC-navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea-cta&uac=148436CN

Building Care Plans With Radiopharmaceuticals for Patients With mCRPC Authors: Neal D. Shore, MD, FACS; Alicia Morgans, MD, MPH, FASCO; Chad Tang, MD

https://www.medscape.org/viewarticle/building-care-plans-radiopharmaceuticals-patients-mcrpc-2026a10007zy?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260510-OUS-HONC-building-care-plans-radiopharmaceuticals-patients-mcrpc-2026a10007zy-cta

HER2 Evolution in Gastroesophageal Cancer: New Therapies and Optimized Outcomes Authors: Samuel J. Klempner, MD, FASCO

https://www.medscape.org/viewarticle/her2-evolution-gastroesophageal-cancer-new-therapies-and-2025a1000x2t?page=1&src=mkmcmr_driv_stan_mscpedu_260510-OUS-HONC-her2-evolution-gastroesophageal-cancer-new-therapies-and-2025a1000x2t-cta&uac=148436CN

Virtual Patient Simulation for CLL: Test Your Skills Authors: Barbara F. Eichhorst, MD; Stephan Stilgenbauer, MD

https://www.medscape.org/viewarticle/virtual-patient-simulation-cll-test-your-skills-2025a1000wjp?page=1&src=mkmcmr_driv_psims_mscpedu_260510-OUS-HONC-virtual-patient-simulation-cll-test-your-skills-2025a1000wjp-cta&uac=148436CN

National Women's Health Week (NWHW) From the FDA Office of Women's Health +... ++++

https://www.fda.gov/consumers/womens-health/national-womens-health-week-nwhw?utm_medium=email&utm_source=govdelivery National Women’s Health Week: Partner Social Media Toolkit From the FDA Office of Women's Health https://www.fda.gov/consumers/womens-health/national-womens-health-week-partner-social-media-toolkit?utm_medium=email&utm_source=govdelivery Know Your Nutrition: Empowering Women to Make Informed Food Choices Knowledge and News on Women’s Health (KNOWH) blog from FDA Office of Women’s Health https://www.fda.gov/consumers/knowledge-and-news-women-owh-blog/know-your-nutrition-empowering-women-make-informed-food-choices?utm_medium=email&utm_source=govdelivery Navigate Food Labels with Confidence: Understanding the Nutrition Facts Label, the Updated “Healthy” Claim, and Other Nutrition Claims May 13, 2026 https://www.fda.gov/consumers/womens-health-events/navigate-food-labels-confidence-understanding-nutrition-facts-label-updated-healthy-claim-and-other?utm_medium=email&utm_source=govdelivery Human Foods Program Also referred to as: HFP https://www.fda.gov/about-fda/fda-organization/human-foods-program?utm_medium=email&utm_source=govdelivery

Female Athlete Triad Awareness for Women and Girls in Sports

https://womenshealth.gov/blog/female-athlete-triad-awareness-women-and-girls-sports Dorothy Fink, M.D. At the HHS Office on Women’s Health, we are committed to empowering women and girls to be active in sports and stay healthy throughout life. There are many sports-related conditions that are more common in women compared to men, including stress fractures, anterior cruciate ligament (ACL) tears, ankle sprains, and recovery time after concussions. This blog shares the steps women and girls can take to prevent complications associated with the female athlete triad, a condition that can impact their ability to participate in the sports and activities that keep them active.

Migraine

https://womenshealth.gov/a-z-topics/migraine Migraine is a medical condition. A migraine headache is usually an intense, throbbing pain on one, or sometimes, both sides of the head. Migraine pain and symptoms affect 29.5 million Americans. About three out of four people who have migraines are women. Migraine is the most common form of disabling headache that sends patients to see their doctors.

Lupus

https://womenshealth.gov/lupus Lupus is a chronic, autoimmune disease that can damage any part of the body, including the skin, joints, and organs inside the body. About 9 out of 10 adults with lupus are women. Some women have only mild symptoms. But, for others, lupus can cause severe problems. Women with lupus need to be especially careful to manage their symptoms when planning a pregnancy.

Early or premature menopause

Early or premature menopause Explore essential information for women experiencing early or premature menopause. Learn about the causes, health impacts, and available treatments to better navigate this transition. https://womenshealth.gov/menopause

Depression

https://womenshealth.gov/mental-health/mental-health-conditions/depression Life is full of ups and downs, but when you feel sad, empty, or hopeless most of the time for at least 2 weeks or those feelings keep you from your regular activities, you may have depression. Depression is a serious mental health condition. In the past year, women were almost twice as likely as men to have symptoms of depression.1 Depression is not a normal part of being a woman. Most women, even those with the most severe depression, can get better with treatment.

Neonatal Abstinence Syndrome/Opioid Withdrawal in the Neonate

https://womenshealth.gov/a-z-topics/neonatal-abstinence-syndrome To improve care for babies exposed to opioids before birth, HHS recently published a standardized definition for diagnosis of opioid withdrawal in neonates, or newborns. In utero exposure – or exposure in the womb before birth – to opioids and other substances can result in withdrawal once a baby is born. The standardized clinical definition is not meant to prove or imply harm but instead ensure babies and families with opioid exposure get the care they need.

Online friendships with strangers linked to greater adult loneliness

https://www.news-medical.net/news/20260508/Online-friendships-with-strangers-linked-to-greater-adult-loneliness.aspx A first-of-its-kind study of U.S. adults suggests that all of those strangers you're friends with on social media are not helping you to feel less lonely.

NWHW 2026 Toolkit - Happy National Women’s Health Week (NWHW) and Happy Mother’s Day!

https://womenshealth.gov/nwhw/resources?utm_medium=email&utm_source=govdelivery

National Women's Health Week 2026 - Happy National Women’s Health Week (NWHW) and Happy Mother’s Day!

https://womenshealth.gov/nwhw?utm_medium=email&utm_source=govdelivery Happy National Women’s Health Week (NWHW) and Happy Mother’s Day! From May 10–16, the HHS, Office on Women’s Health (OWH) highlights health conditions and priorities that affect women and girls and encourages everyone to take charge of their physical, mental, and emotional well-being. This year’s theme, “Prevention, Innovation, and Impact: A New Era in Women’s Health,” emphasizes proactive, science-driven, and coordinated approaches to care. It calls for a shift away from fragmented models toward strategies that prioritize prevention, early detection, and measurable outcomes. The theme also highlights emerging science, underscores the importance of early detection and prevention, recognizes the role of hormones in whole-person health across the lifespan, and ensures content is grounded in current and emerging research in women’s health. During the week, visit https://www.womenshealth.gov/nwhw to explore our four focus areas and access an array of helpful resources, including a toolkit complete with social media shareables, graphics, and fact sheets that support these topics: Prevention & Early Detection Across the Lifespan Sex-Specific Biology and Hormonal Foundations of Women’s Health Chronic Disease, Midlife Health, Aging, & Longevity Innovation, Translation, & the Future of Women’s Health https://womenshealth.gov/nwhw/resources?utm_medium=email&utm_source=govdelivery

Ultraprocessed Food Linked to Increased Dementia Risk, Poor Attention Edited by Anushree Chaphalkar May 08, 2026

https://www.medscape.com/viewarticle/ultraprocessed-food-linked-increased-dementia-risk-poor-2026a1000euw?ecd=wnl_tp10_daily_260510_MSCPEDIT_etid8327124&uac=148436CN&impID=8327124

Could genotype testing finally change how SSRIs are prescribed for depression? (Medscape AI)

https://www.medscape.com/ai-search?query=Could%20genotype%20testing%20finally%20change%20how%20SSRIs%20are%20prescribed%20for%20depression%3f&ecd=wnl_tp10_daily_260510_MSCPEDIT_etid8327124&uac=148436CN&impID=8327124

Optimizing First-Line Care in BRAF-Mutated mCRC: A Multidisciplinary, Patient-Centered Approach Authors: Elena Elez, MD, PhD; Sebastian Stintzing, MD; Umberto Malapelle, PhD

https://www.medscape.org/viewarticle/1003328

Emerging Frontiers in Immunotherapy: Bridging Data and Practice in Solid Tumors Authors: Timothy A. Yap, MBBS, PhD, FRCP; Suresh S. Ramalingam, MD, FASCO; Hussein Tawbi, MD, PhD

https://www.medscape.org/viewarticle/emerging-frontiers-immunotherapy-bridging-data-and-practice-2026a1000es5?page=1

May 08, 2026 This Week in Cardiology Podcast John M. Mandrola, MD May 08, 2026

https://www.medscape.com/viewarticle/1003362?ecd=wnl_edit_tpal_etid8330682&uac=148436CN&impID=8330682

Chronic Lymphocytic Leukemia (CLL): Review of Combination Approaches Authors: Jonathon Cohen, MD, MS; Matthew S. Davids, MD, MMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku?page=1&src=mkmcmr_driv_stan_mscpedu_260509-OUS-HONC-chronic-lymphocytic-leukemia-cll-review-combination-2026a10004ku-cta&uac=148436CN

How Much Monitoring Is Enough in Psoriasis Care? Medscape InDiscussion Psoriasis Show Image Steven R. Feldman, MD, PhD; Jennifer C. Cather, MD; Brad P. Glick, DO, MPH, FAAD, FAOCD

https://www.medscape.com/ca8/p04/podcast-psoriasis-s4-ep3-2026a10006hk?ecd=mkm_mscpapp_260509_mscpmrk_podcasts_etid8327905&uac=148436CN&impID=8327905

Don't Miss the Zebra: AI in ATTR-CM photo of Transthyretin Amyloid Cardiomyopathy Kevin M. Alexander, MD; Lily K. Stern, MD

https://www.medscape.com/ca8/p04/podcast-attr-cm-s1-ep3-2026a10006hb?ecd=mkm_mscpapp_260509_mscpmrk_podcasts_etid8327905&uac=148436CN&impID=8327905

Route 66 SPORE and the Direction of Endometrial Cancer Research InDiscussion Endometrial Cancer Show Image Ursula A. Matulonis, MD; David G. Mutch, MD

https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep2-2026a10006ic?ecd=mkm_mscpapp_260509_mscpmrk_podcasts_etid8327905&uac=148436CN&impID=8327905

Apr 24, 2026 This Week in Cardiology Podcast John M. Mandrola, MD April 24, 2026

https://www.medscape.com/viewarticle/1003347#vp_3?ecd=mkm_mscpapp_260509_mscpmrk_podcasts_etid8327905&uac=148436CN&impID=8327905

Navigating the HER2 Spectrum in Breast Cancer: Evolving Diagnostic Paradigms for Clinical Excellence Authors: Sara M. Tolaney, MD, MPH; Frédérique Penault-Llorca, MD; Giuseppe Curigliano, MD, PhD

https://www.medscape.org/viewarticle/navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260509-OUS-HONC-navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea-cta

Patient dignity in mental health care: from inherent worth to standing Caner Turan* [1] , Oliver Sensen [2]

https://www.academia.edu/2997-9196/3/1/10.20935/MHealthWellB8168 Respect for patient dignity is recognized as an ethical commitment in healthcare, yet the concept often remains too abstract to guide clinical practice. This challenge is salient in mental health contexts, where patients may experience diminished autonomy, stigma, or institutional constraints. This paper develops a conceptual and normative analysis of dignity in mental health care by distinguishing between two conceptions: dignity as inherent worth and dignity-as-standing. Drawing on philosophical analysis, empirical literature, and global policy frameworks, the paper evaluates each conception’s practical implications for care. We argue that while dignity as inherent worth understands dignity as an intrinsic, non-natural value grounding human rights, it often remains too vague to guide clinical decision-making and may risk excluding patients with diminished autonomy. By contrast, dignity-as-standing conceives dignity not as a metaphysical value but as the elevated moral standing of persons that calls for treatment befitting their rank as members of the moral community. This conception offers a more action-guiding and inclusive framework for care, especially for patients with mental illness, disabilities, dementia, or advanced age. On this basis, we identify strategies for operationalizing dignity in practice, including recognizing autonomy as a continuum, implementing supported decision-making, respecting value-based refusals, and embedding relational, structural, and culturally responsive supports in care. The dignity-as-standing framework offers a practical and ethically coherent foundation for respecting patients’ dignity in mental health care, enabling clinicians and institutions to translate the ideal of dignity into concrete practices across diverse clinical and cultural contexts. https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav Technological mourning after AI updates: mental health and well-being in the GPT-4o/GPT-5 transition Véronique Donard, José Carlos Ribeiro Volume 3, Issue 2 Special Issue: Cognitive and Emotional Perception of Digital Environments: Implications for Mental Health

Researchers uncover how bacterial toxin damages colon lining cells to trigger cancer

https://www.news-medical.net/news/20260508/Researchers-uncover-how-bacterial-toxin-damages-colon-lining-cells-to-trigger-cancer.aspx Since a landmark 2009 study, researchers have known that a common gut bacterium, Bacteroides fragilis, drives colon tumor formation, potentially leading to colorectal cancer, by secreting a toxin that damages the lining of the colon. But until now, the exact mechanism the toxin uses to latch onto those cells remained a mystery.

Improving Outcomes in Advanced Resectable CSCC: An Expert Viewpoint on the Role of Immunotherapy Authors: Emily Ruiz, MD, MPH

https://www.medscape.org/viewarticle/improving-outcomes-advanced-resectable-cscc-expert-viewpoint-2026a100050y?page=1&src=mkmcmr_driv_stan_mscpedu_260509-OUS-HONC-improving-outcomes-advanced-resectable-cscc-expert-viewpoint-2026a100050y-cta&uac=148436CN

DIGITAL DANGERS: CRIME WITHOUT CONTACT

Digital dangers aren’t just annoying; they’re costing Americans billions. More than half of adults say they’ve been targeted by a scam through email, text or phone. See the new digital threats most people don’t see coming.

DE-AGE YOUR BRAIN: THE 5 DAY RESET

More than seven million Americans age 65 and older are living with Alzheimer’s disease! That number is expected to nearly double by 2050, but researchers say some of the most powerful tools for protecting the brain may be the things you do every day!

THE RETIREMENT CRISIS NO ONE WARNS YOU ABOUT: MATTERING

This year alone, more than four million Americans are expected to turn 65 and reach traditional retirement age. While many plan for the financial side of retirement, experts say there’s a risk few people prepare for…losing their sense of purpose.

WOMEN’S HEALTH WEEK: TESTS EVERY MOM SHOULD GET

National Women’s Health Week starts May 10th, a reminder for women to put their health first. A recent survey found more than six in 10 women say they struggle to make their own health a priority. Missing routine screenings can mean missing early warning signs of serious disease. What are they? Take a look here.

Grandparents Going Broke: Love, Family & The Financial Risk By Ivanhoe Broadcast News on May 15, 2026

Orlando, Fla. (Ivanhoe Newswire) — Grandparents love spoiling their grandkids, but more and more families are relying on grammy and gramps for financial help. Surveys show nearly half of grandparents say they help pay for things like school expenses, activities, and childcare but that generosity can come at a cost, because research shows nearly 40 percent of households approaching retirement have no retirement savings at all. Many grandparents say they feel pressure to give, even when it stretches their own budget. https://www.ivanhoe.com/?p=37037&preview=1&_ppp=c734141888

The Great Spring Energy Crash By Ivanhoe Broadcast News on May 14, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — Spring is a time to start fresh… or not. Unlike general fatigue, spring fatigue is directly tied to seasonal transitions. The body goes through adjustments as it adapts to changes in daylight and temperature. This can throw off internal balance and make people feel more drained than usual. https://www.ivanhoe.com/?p=37048&preview=1&_ppp=caedc3d24f

Gene Therapy Heals Broken Hearts: No Surgery Needed! By Ivanhoe Broadcast News on May 13, 2026

RALEIGH, NC. (Ivanhoe Newswire) — Heart disease remains the leading cause of death in the United States, responsible for about one in every five deaths each year. And worldwide, cardiovascular disease claims nearly 18 million lives annually, more than any other condition. Now researchers are working on a new way to help hearts heal after a heart attack, not with surgery or stents, but with gene therapy designed to strengthen the heart from within. https://www.ivanhoe.com/?p=37045&preview=1&_ppp=f656e2b67e

Tiny Guts, Tough Fight: Celiac Disease in Children By Ivanhoe Broadcast News on May 12, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — Celiac disease is something that most people may not know they have. Studies show that as many as one in every 141 Americans may have celiac disease, but in children’s cases, they’re underdiagnosed. Research shows that only one in 10 children with high-risk symptoms and conditions are being tested for celiac disease. Now, for celiac awareness month, experts say recognizing the signs early can make a difference. https://www.ivanhoe.com/?p=37043&preview=1&_ppp=cebc1dae1c

What You Need to Know About C-sections By Ivanhoe Broadcast News on May 11, 2026

ORLANDO, Fla. (Ivanhoe Newswire) — The U.S. has about 10,000 births per day, and about 32% of those births are via cesarean section, or C-section. If that number feels high for you, you’re not alone. The World Health Organization says the acceptable rate is only 10-15%. https://www.ivanhoe.com/?p=37040&preview=1&_ppp=a93ead928e

Beyond PSMA: Preparing Your Practice for the Next Wave of Prostate Cancer Biomarkers Authors: Karim Fizazi, MD, PhD; Bertrand Tombal, MD, PhD; Alberto Briganti, MD, PhD

https://www.medscape.org/viewarticle/beyond-psma-preparing-your-practice-next-wave-prostate-2026a10006ql?page=1&src=mkmcmr_driv_stan_mscpedu_260509-OUS-HONC-beyond-psma-preparing-your-practice-next-wave-prostate-2026a10006ql-cta&uac=148436CN